Gathering the record
Relay is organizing the evidence and source boundaries.
Informal multi-compound blend label
GLOW is a community label commonly used for a mixture described as GHK-Cu, BPC-157, and TB-500. Each ingredient has a different evidence record, and no study was located testing all three together.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
GLOW is a community name for a mixture usually described as GHK-Cu, BPC-157, and TB-500. It is not one standardized compound or a verified clinical-study product.
The name combines three separate repair-related stories into one product idea. That makes identity, compatibility, and direct combination evidence more important than the biological appeal of any individual ingredient.
Relay found no controlled human study testing the three-component blend. Limited component evidence includes formulation-specific topical GHK-Cu research, an unfinished BPC-157 trial, and laboratory or animal TB-500 work; those records cannot be added together as proof of the mixture.
The blend's actual ingredients and ratio, stability after mixing, sterility, interactions, human exposure, safety, and clinical effects remain unknown. A label using the name GLOW does not establish that two products share the same identity.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
No verified study was located that administered GHK-Cu, BPC-157, and TB-500 together as one reproducible GLOW formulation. Separate ingredient records are not a combination study.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The available record consists of separate-component evidence and documented searches that found no exact-combination study.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
No direct evidence establishes benefit, synergy, compatibility, stability, safety, or pharmacokinetics for the three-component mixture.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Component studies use different identities, routes, formulations, populations, and outcomes. The section remains incomplete because blend-specific compatibility, exposure, safety, and outcome evidence do not exist in the reviewed record. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
None for GLOW as a blend. The strongest component-level human evidence comes from specific topical GHK-Cu studies; it cannot establish injectable GLOW.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The blend's actual identity and ratio, chemical and physical compatibility, stability after mixing, sterility, pharmacokinetics, interactions, immunogenicity, dose-response, safety, and clinical effects.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Peptide Relay uses GLOW to organize discussion of mixtures labeled as GHK-Cu, BPC-157, and TB-500. The name does not define a regulator-recognized identity, fixed ratio, formulation, or quality standard.
Searches of PubMed and ClinicalTrials.gov through July 25, 2026 did not identify a study administering all three together.
The three component records involve different routes, formulations, evidence levels, populations, and endpoints. Separate findings do not demonstrate synergy or a combined clinical effect.
GHK-Cu has mixed formulation-specific topical human research; BPC-157 has small uncontrolled reports and a registered Phase 2 trial without results; FDA found no human TB-500 administration by any route.
Only four people received the two-material treatment, no one received GHK-Cu, there was no comparison group, and the report does not establish that its thymosin-beta-4 material was the seven-amino-acid TB-500 fragment.
Different proposed pathways do not show that the ingredients remain chemically stable together, avoid aggregation, or produce a favorable biological interaction.
No regulator-approved fixed-combination product or combination study provides a universal preparation, administration, or handling process.
GHK-Cu, BPC-157, and TB-500 have different regulatory histories. Advisory votes or category placement for an ingredient do not establish approval, safety, effectiveness, or eligibility of a fixed combination.
Mechanisms
The proposed components differ in identity, formulation, and evidence maturity. GHK-Cu is a copper-binding tripeptide with mixed, condition-specific topical human evidence. BPC-157 is a synthetic pentadecapeptide with predominantly preclinical evidence, small uncontrolled human reports, and a registered Phase 2 trial without results. TB-500 is an N-acetylated seven-amino-acid thymosin-beta-4 fragment for which FDA located no human administration. No pharmacokinetic, stability, compatibility, interaction, safety, or efficacy study of the exact three-component combination was located.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized topical GHK-Cu program with standardized diabetic-ulcer care
Adults with diabetic neuropathic plantar ulcers
An immediate-treatment plantar-ulcer analysis reported more complete closure with topical GHK-Cu than vehicle.
Study administration: Topical GHK-Cu gel plus wound care versus vehicle plus wound care
Limitations: This tested a topical GHK-Cu formulation in a defined wound population. It does not test BPC-157, TB-500, injection, mixing, or the GLOW combination.
TB-500 metabolism in human-derived in-vitro systems and rats, with fibroblast scratch-wound assays
Human serum and microsomal systems, cultured fibroblasts, and rats
Parent TB-500 did not improve fibroblast scratch-wound closure at the tested concentration; one shorter metabolite showed activity.
Study administration: TB-500 free base and synthesized metabolites under laboratory protocols
Limitations: This is laboratory and animal component evidence. It does not establish human TB-500 benefit or any finding for a three-component mixture.
Uncontrolled retrospective report of intra-articular treatment for knee pain
16 people with several types of knee pain
Fourteen of 16 people reported relief overall. Three of the four people in the two-material subgroup reported relief.
Study administration: Twelve received BPC-157 alone; four also received material described as thymosin beta-4. No GHK-Cu was used.
Limitations: There was no control group, standardized outcome assessment, or GHK-Cu. The four-person subgroup cannot establish a combination effect, and material described as thymosin beta-4 is not verified as the seven-amino-acid TB-500 fragment.
Randomized, double-blind, placebo-controlled BPC-157 trial with standardized rehabilitation
Adults aged 18–45 with MRI-confirmed acute grade II hamstring strain
No results are posted. The registration cannot establish benefit for BPC-157 or for any blend.
Study administration: Protocol-defined subcutaneous investigational BPC-157 or placebo; no GHK-Cu or TB-500
Limitations: This is an unfinished single-component trial. It provides no evidence about GLOW, ingredient compatibility, or combination effects.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNo FDA-approved GHK-Cu/BPC-157/TB-500 fixed-combination product was located. Ingredient-level compounding reviews and advisory actions do not approve the blend. The blend's actual identity and ratio, chemical and physical compatibility, stability after mixing, sterility, pharmacokinetics, interactions, immunogenicity, dose-response, safety, and clinical effects.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-07-25
2026-07-25
2026-07-23
2026-07-21
2026-05-14
2026-02-27 · NCT07437547
2024-03-15 · PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
2021-07-01 · PMID 34324435
1994-10-01 · PMID 17147644 · DOI 10.1046/j.1524-475X.1994.20406.x
No direct primary administration source was verified for this exact identity. The limitation is the finding.